IGC Pharma Advances Alzheimer’s Drug Targeting Agitation and Disease Progression

IGC Pharma is advancing a promising Phase 2 clinical trial targeting agitation in Alzheimer’s patients, with enrollment already over 70% complete. The company’s oral therapy aims to address one of the most challenging symptoms of the disease, improving quality of life for both patients and caregivers.

Beyond symptom relief, IGC is exploring the potential for its drug to impact the underlying disease itself, including reducing plaque buildup and protecting neurons. With plans for potential partnerships or Phase 3 development ahead, the company is positioning its therapy as a significant opportunity in a rapidly growing global market.

#IGCPharma
#Alzheimers
#Biotech
#ClinicalTrials
#Neuroscience
#DrugDevelopment
#MentalHealth
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#NeurodegenerativeDisease
#BiotechInvesting
#Innovation
#Healthcare
#NewsOut